densest galaxy known in the local universe,


Densest galaxy ever discovered


WASHINGTON: Astronomers have discovered the densest galaxy ever to be found - packed with an extraordinary number of stars - about 54 million light years from our own Milky Way.
The ultra-compact dwarf galaxy, dubbed M60-UCD1, was found in what's known as the Virgo cluster of galaxies, researchers said.
Imagine the distance between the Sun and the star nearest to it - Alpha Centauri. That's a distance of about 4 light years. Now, imagine as many as 10,000 of our Suns crammed into that relatively small space.
That is about the density of a galaxy discovered by an international team of astronomers led by a Michigan State University faculty member.
"This galaxy is more massive than any ultra-compact dwarfs of comparable size and is arguably the densest galaxy known in the local universe," said Jay Strader, MSU assistant professor of physics and astronomy.
The galaxy was discovered in the Virgo cluster of galaxies, a collection of galaxies located about 54 million light years from our own Milky Way.
What makes M60-UCD1, so remarkable is that about half of its mass is found within a radius of only about 80 light years. This would make the density of stars about 15,000 times greater than found in Earth's neighbourhood in the Milky Way.
"Travelling from one star to another would be a lot easier in M60-UCD1 than it is in our galaxy. Since the stars are so much closer in this galaxy, it would take just a fraction of the time," Strader said.
The discovery of ultra-compact galaxies is relatively new - only within the past 10 years or so. Until then, astronomers could see these "things" way off in the distance but assumed they were either single stars or very-distant galaxies.
Another intriguing aspect of this galaxy is the presence of a bright X-ray source in its centre. One explanation for this is a giant black hole weighing in at some 10 million times the mass of our Sun.

World’s first: A car driven by attention


MELBOURNE: Researchers claim to have developed the world's first attention-powered car — a pioneering vehicle that uses a headset to monitor brain activity and slow acceleration during periods of distraction.

The car commissioned by the The Royal Automobile Club of West Australia was tested in Perth in a bid to prevent road accidents due to inattention. The makers describe it as a "car that goes when you're paying attention, and slows when you're not."

The technology behind the vehicle uses a neuro headset that connects to brain activity linked to the car's engine via customized software, 'PerthNow' reported. The software communicates with the car and slows the vehicle when the driver's concentration lapses. The headset measures the electrical activity in a person's brain and feeds it into an algorithm that determines if the driver is paying attention or not.

genomic therapies to tackle tumor-prone years


Treatment for cancer lies in our genes


NEW DELHI: It's a warning that should be heeded. Even as experts say that the US will face a crisis in cancer care as an aging population reaches its tumor-prone years, scientists have developed revolutionary genomic therapies to tackle this looming crisis. So revolutionary, in fact, that the treatment for cancer now lies in our genes itself.

Most cancers have variations which can be decoded by their DNA. Specific tests now zero in on these DNA, leading to targeted treatment. "Previously, cancers were treated with a crude approach using multiple chemotherapy drugs with many side-effects," says Dr S V S Deo, associate professor, department of surgical oncology, All India Institute of Medical Sciences, Delhi. "Targeted therapy is like a 'smart bomb' which specifically attacks cancer cells without harming normal tissues and has minimal side effects." It is being used successfully for breast, lung, gastrointestinal and blood cancer.

The success of these biological therapies depends on identifying the defect in a cancer cell, says Dr Radheshyam, consultant, medical oncologist, HCG Cancer Centre, Bangalore. "In some tumors, precision medicine is going to be a significant part of overall treatment. While there are hundreds of chemotherapy drugs, in advanced cancers, both chemo and targeted therapy are given."

These therapies are especially beneficial for hereditary cancer and selectively kill cancer cells by interacting with the receptors. "Some targeted therapies even have the advantage that they lead to minimal hair loss," says Dr Sunil Kumar Gupta, senior consultant, Rajiv Gandhi Cancer Institute and Research Centre, Delhi.

For these biological therapies, first tissue is taken from the tumour and a DNA test done. This will show up genetic abnormalities and mutations. Sometimes a drug that works on a mutated lung cancer cell can also work for some other cancer. So scientists have to find which treatment works for which mutation in which organ.

There are different DNA tests for different cancers depending on their mutations. For example, BRCA testing helps in identifying women at risk for developing breast cancer with a family history. "Gene profiling tests like Oncotype Dx and mamma print help in knowing the risk of cancer recurring and the treatment can be tailored to the patient's needs. They also provide information on the need for chemotherapy," says Deo. Oncotype Dx is, however, done by labs in the US.

Oncotype Dx, says Gupta, analyzes 21 genes in a tumor to determine whether the patient should be given only hormonal therapy (for low risk patients) or chemotherapy (high risk). For lung cancer, EGFR, AIK and Her-2 gene tests are done and for colorectal cancer, K-ras gene mutation analysis.

These revolutionary treatments are a mind-boggling field and expensive with the costs varying between Rs 3 lakh to Rs 10 lakh, says Deo. While some 25% of cancer patients at AIIMS receive some form of targeted therapy, at HCG hospital more than 100 patients have been treated with this procedure. And at Rajiv Gandhi Cancer Institute, plans are afoot to start a Hereditary Genetic Cancer Clinic.